Med. praxi. 2011;8(7):316-320
Hypolipidemic therapy in the hands of a general practitioner
- 3. interní klinika VFN a 1. LF UK, Praha
Cardiovascular disease is the most common cause of mortality and morbidity in the Czech Republic. Dyslipidemia is one of the causal
parameters by affecting which the cardiovascular risk can be reduced substantially. Selecting a proper hypolipidemic drug is often crucial
in selectively affecting the lipid spectrum. If possible, it is necessary to adhere to the recommended target levels as closely as possible.
On the other hand, however, it is necessary to realize that the treatment often has to be individualized. In hypolipidemic therapy, monitoring
the patient’s lipid panel as well as the “safety” indicators is of importance. The administration of hypolipidemic drugs is safe and
laboratory markers need to be correlated with possible subjective complaints of the patient. Only a comprehensive intervention with
all the risk factors may result in an effective reduction in the cardiovascular risk of the patient.
Keywords: dyslipidemia, hypolipidemic therapy
Published: August 1, 2011 Show citation
References
- Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, Piťha J, Poledne R, Štulc T, Urbanová Z, Vráblík M. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitřní lékařství 2007; 53(2): 181-197.
Go to PubMed... - www.athero.cz.
- http://www.biomed.cas.cz/fgu/aip/kalkulator.php.
- Dobiášová M. AIP - Aterogenní index plazmy jako významný prediktor kardiovaskulárního rizika: od výzkumu do praxe, Vnitř Lék 2006; 52(1).
- Češka R. Cholesterol a ateroskleróza, Maxdorf, 2007, Praha.
- Vrablík M, Česka R, Fait T: Otazníky kardiovaskulární prevence, Facta Medica 2009.
- SPC přípravku atorvastatin, simvastatin, rosuvastatin, fenofibrát, www.sukl.cz.